Sean Nolan

Sean Nolan General Information

Biography

Mr. Sean Nolan serves as Chief Executive Officer & Chairman at Taysha Gene Therapies. Mr. Nolan serves as Chairman at Jaguar Gene Therapy. He also serves as Chairman at Istari Oncology. He was a Board Member and also served as the Chief Executive Officer and President at AveXis. He served as Chairman at Axovia Therapeutics. Before joining us, from February 2013 to April 2015, he was the chief business officer of InterMune Inc., a biotechnology company later acquired by Roche Holding AG. While at InterMune, he led multiple functions across the organizations, including North American commercial operations, global marketing, corporate and business development, and global manufacturing and supply chain. He was also responsible for planning and executing the U.S. launch of InterMune's treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no other approved treatments. He served as a chief commercial officer at Reata Pharmaceuticals, Inc. from August 2011 to December 2012, where he led the market strategy development and commercialization of Reata Pharmaceuticals' first-in-class product pipeline. From September 2004 to November 2010, he worked at Ovation Pharmaceuticals, Inc., a company focused on orphan neurology diseases. He held numerous management positions during that period including President of Lundbeck Inc., a U.S. affiliate. Ovation Pharmaceuticals was acquired by H. Lundbeck A/S in March 2009 for $900 million. He holds a B.A. in biology from John Carroll University. he currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. Our board of directors believes that he is qualified to serve as a director based upon his role as our principal executive officer, and his 24 years of broad leadership and management experience in the biopharmaceutical industry.